CSIMarket
 
Arca Biopharma Inc   (ABIO)
Other Ticker:  
 
 
Price: $1.6900 $-0.01 -0.588%
Day's High: $1.73 Week Perf: 2.74 %
Day's Low: $ 1.68 30 Day Perf: 3.05 %
Volume (M): 47 52 Wk High: $ 2.16
Volume (M$): $ 79 52 Wk Avg: $1.92
Open: $1.73 52 Wk Low: $1.56



 Market Capitalization (Millions $) 24
 Shares Outstanding (Millions) 14
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Arca Biopharma Inc
Arca Biopharma Inc is a biopharmaceutical company that focuses on the development and commercialization of treatments for cardiovascular diseases. The company primarily focuses on developing genetically-targeted therapies, using its proprietary technology to identify and select patients who are most likely to benefit from certain treatments. Arca Biopharma aims to improve the effectiveness and safety of current treatment options for cardiovascular diseases, such as heart failure and atrial fibrillation. They collaborate with leading academic institutions and research organizations to advance their drug development programs.


   Company Address: 10170 Church Ranch Way Westminster 80021 CO
   Company Phone Number: 940-2200   Stock Exchange / Ticker: NASDAQ ABIO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Arca Biopharma Inc

Arca Biopharma Inc Surges in Q3 2023, Delivering Positive News for Investors with a Decreased Operating Shortfall

Over the past five days, the stock of Arca Biopharma Inc has experienced a slight decrease of -0.25%. This decline contributes to a year-to-date performance of -15.91%, indicating a challenging period for the company's stock value. However, it is worth noting that despite this decrease, Arca Biopharma Inc's stock is still trading 10% above its lowest point in the past 52 weeks.
During the current earnings season, which encompasses the period from July to September 30, 2023, numerous corporations across various sectors have been announcing their financial results. Within the In Vitro & In Vivo Diagnostic Substances sector, Arca Biopharma Inc is one of the entities that have disclosed their performance.
Arca Biopharma Inc recently reported an operating shortfall of $-1.937 million for the fiscal interval ending on September 30, 2023. Compared to the third quarter of 2022, where the operating shortfall reached $-2.552 million, this is an improvement and a positive signal for the state of the company. Examining the numbers in more detail, the deficit has decreased from $-2.333 million in the third quarter of 2022 to $-1.424 million in the same period this year. This decline in the shortfall is a promising revelation and indicates progress towards a more successful future for Arca Biopharma Inc.

Arca Biopharma Inc

Arca Biopharma Inc's Operative Deficit of $-1.973 Million Spurs Surge in Biotechnology & Pharmaceuticals Stocks

As a stock market journalist, I have been closely following the financial results of various companies in the Biotechnology & Pharmaceuticals industry. While the big players in this industry dominate the headlines, it is important to pay attention to the lesser-known businesses as well, as they often provide interesting insights into the sector. One such company is Arca Biopharma Inc.
In the second quarter of 2023, Arca Biopharma Inc reported an operating deficit of $-1.973 million, which is a significant improvement compared to the same period last year. This recent performance on the operating stage has surpassed expectations and indicates promising growth potential for the company. It is worth noting that Arca Biopharma mainly operates in the research stage, making the results of this report particularly crucial.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com